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Haemostasis is a mechanism that, through different interdependent biologic processes, has the purpose of ensu-
ring the integrity and permeability of the circulatory system. Hemostasis term means prevention the loss of blood. 
Interventions or treatments in the oral cavity, in particular those with a possibility of bleeding, represent a risk for 
patients with disorders of hemostasis. Prevention is the key to avoid bleeding complications after oral surgical 
procedures and therefore it is essential a detailed medical history of the patient.
The appropriate diagnosis and treatment in patients with disorders of hemostasis, depends directly in the understan-
ding of hemostasis standard mechanisms. Emphasising not only the importance of a thoughtful insight into these 
mechanisms, but also of the existing analysis that study them.
This paper makes a synthesis of the general aspects of inherited coagulation disorders (Von Willebrand disease and 
Hemophilia A and B) as well as of the alterations on platelets consequence of the use of certain medication (anti-
platelet and anticoagulant drugs), and their dental management.
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Introduction
A common complication that arises in patients with 
disorders of hemostasis after oral surgery is excessive 
bleeding. The best strategy to avoid these hemorrhagic 
complications in interventions in the oral cavity is pre-
vention. This approach finds indispensable a detailed 
medical history of the patient (1-4) and requires compre-
hension of the physiology of haemostasis. The medical 
history will emphasise on previous bleeding events after 
any intervention, labor or dental extraction, as well as 
any personal and family precedents that could influence 
an effective hemostasis. Figure 1 shows the current coa-
gulation cascade.
Coagulopathies constitute a heterogeneous group of di-
seases that cause hemorrhagic diatheses, and are conse-
quence of quantitative or qualitative alterations of the 
plasma proteins involved in any of the phases of blood 
coagulation (platelet, vascular, coagulation, fibrinoly-
sis). Diseases are classified into congenital or inherited 
and acquired, being possible to have both types coexis-
ting in the same patient, as for example a patient with 
haemophilia A and liver disease. Von Willebrand disea-
se (vWD) is the most common within these inherited 
diseases, caused by deficiency in quantity or fault in 
functionality of the Von Willebrand factor (vWF). VWD 
transmits commonly as autosomal dominant or less fre-
quently as recessive, with an estimation between 1% 
and 2% of affected population. Moreover, hemophilia 
is also an inherited disease consequence of the activity 
deficiency of Factor VIII (FVIII) (Hemophilia A or clas-
sic) or Factor IX (FIX) (Hemophilia B or Christmas di-
sease). The prevalence is estimated of 1-5.000 in males 
with hemophilia A and of 1/30.000 with hemophilia B. 
Hemophilia is transmitted as recessive inheritance asso-
ciated to chromosome X (heritage linked to gender), and 
consequently women pass on the defect without suffe-
ring the effects. 
Antiplatelet drugs are frequently used for prevention of 
arterial and venous thrombosis in patients suffering di-
seases like ischemic cardiopathy, as well as on carriers 
of prosthetic heart valves and coronary endoprosthesis 
(stent) and patients with risk of experimenting an ische-
mic stroke. Furthermore, patients following treatments 
with antiplatelet drugs have an increased tendency to ge-
neral bleeding, as antiplatelet mechanism consist in the 
inhibition of platelet functions. Dentistry professionals 
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is estimated that 1% to 2% of the population is affected 
by the vWD (12).
The vWF is a synthetic glycoprotein synthesized and 
stored in the megakaryocyte and in the endothelial cells, 
which function is to act as a bridge between platelets and 
sub endothelial structures, amid them, collagen benefits 
the platelets adhesion. Three main functions are iden-
tified: platelets adhesion to the endothelium, adhesion 
between platelets and the transportation of FVIII (4,6). 
VWD constitute an heterogeneous group with a large 
phenotypic variety, which justifies the different grades 
of haemorrhage intensities, predominantly mild variety. 
The vWD can be classified into different types depen-
ding on the amount of vWF affected (6, 10):
Type I is the most common, it is autosomal domi-• 
nant (70-75%); consists of a quantitative decrease 
of vWF in the plasma.
Type II, the vWF is qualitatively abnormal, deriving • 
into anomalous binding  to its platelet receptor, the 
Glycoprotein Ib (GPIb); identifying within it three 
subtypes. 
Type III is a severe variant, transmits as an autoso-• 
mal recessive inheritance making patients incapable 
of synthesising vWF (4,6).
The main symptoms may arise as mucosal hemorrha-
ge (menorrhagias, epistaxis,…) (6,9-11), bleeding after 
dental extraction or postpartum (1-4).
The therapeutic options for the vWD are: 1-Deamino-
8-D-arginine Vasopressin (DDAVP), antifibrinolytic 
agents, sinthetic estrogen and substitutive treatments 
with FVIII concentrate rich in vWF (1,4,6). 
Depending on the cuantity and type of hemorrhage as 
well as of the reaction obtained from the DDAVP, they 
can be administrated alone or combined. 
The DDAVP (Desmopressin Acetate) is a synthetic ana-
logous of the vasopressin capable of releasing from the 
vascular vWF endothelial to the bloodstream, increasing 
4-5 times its basal value during 8-10 hours. The effecti-
veness is subjected to patients that synthesize normally 
the vWF, with type I (10). The dose for the intravenous 
injection is of 0,3 μg/kg in 50-100 cc salino during a 
period of time of 20-30 minutes. It can also be adminis-
trated through subcutaneous injection or intranasal (1).
The substitutive treatment with hemoderivatives is 
effective in all subtypes of the vWD, however, due to 
the residual risk of transmissible diseases and its high 
cost, this are held for patients that are not eligible for the 
farmacologic treatment (without response to the DDA-
VP, Tachyphylaxis, etc.) 
- Hemophilia A and B:
First known congenital coagulopathy and the most com-
mon. Is an inherited disease consequence of the lack of 
activity of the FVIII (hemophilia A or classic) or the FIX 
(hemophilia B or Christmas disease) (5). The prevalence 
is estimated to be of 1-5.000 males in haemophilia A and 
have to take into account the risk of an oral hemorrhage 
during and after an invasive dental procedure. Patient’s 
carriers of coronary stents are subject to single or combi-
ned antiplatelet therapy. On the other hand, oral anticoa-
gulants are used in treatments for venous thromboembo-
lism and in the prevention of heart attack and systematic 
embolism in patients with auricular fibrillation, cardiac 
valvular disease or with metallic valve prostheses. Now 
a days, warfarin sodium and acenocoumarol are the 
most common oral anticoagulants; these drugs require a 
correct monitorisation with INR (International Normali-
zed Ratio) (5) in order to adjust the dose and achieve the 
desired therapeutic action. The objective is to minimise 
any adverse effects consequence of either the excess of 
anticoagulation producing hemorrhages or not reaching 
the required level leading to thrombosis. This is critical 
when these patients are subject of surgical procedures 
like tooth extractions, and there are established guideli-
nes to proceed.  
In general terms, almost all authors agree that stopping 
anticoagulant or antiplatelet therapy is dangerous. This 
will increase blood clotting capacity or platelet aggrega-
tion, rising the risk of thromboembolism episodes.
The objectives of this paper are:
Carry out a literature review of the pathological • 
conditions that can produce disturbances in the coa-
gulation or platelets aggregation, including both in-
herited as well as acquired.
Establish the guidelines in dental management of • 
the patients with disorders in blood coagulation and 
platelet aggregation.
Material and Methods
The methodology used through the research for the lite-
rature review includes de following sources: Pubmed-
Medline database, the medical journal Medicine, the data 
base of University of Valencia and specialised published 
books in general medicine as well as in dentistry. 
In Pubmed-Medline data base, the research proceeded 
by searching the next keywords: hemostasis alteration, 
hemostasis disorder, blood coagulation disorders, den-
tal management anticoagulated, oral surgery anticoa-
gulated, antithrombotic drugs, tranexamic acid, epsilon-
aminocaproic acid, INR, warfarin, aspirin. 
In order to narrow down the research, the data was fil-
tered down limiting to papers in English and Spanish, 
within dental journals and not older than 10 years.
Results and Discussion
Congenital bleeding disorders: 
- Von Willebrand disease 
The vWD is the most frequent inherited pathology, cau-
sed by the deficiency in quantity or fault in functionality 
of the vWF (4,6-11), and as mentioned its transmission 
is autosomal dominant or less frequently as recessive. It 
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1/30.000 in type B (1,4). The transmission is as a reces-
sive inheritance associated to chromosome X (heritage 
linked to gender), resulting in female transmitting but 
not suffering it, except for the infrequent case where fa-
ther is hemophilic and the mother is a carrier (1,4,6,12). 
Both haemophilias, A and B are clinically indistinguis-
hable. 
Hemophilia can be classified as severe, moderate and 
mild. Severe haemophilia will normally be diagnosed 
before six months and its main characteristics are an ac-
tivity of the FVIII below 1% of the normal activity and 
spontaneous bleeding. Moderate will show activity va-
lues between 1% and 5% and with hemorrhage episodes 
after surgery, small traumatisms and it arises around 2 
years. The classified as mild has an activity of 5%-25% 
of the normal activity and haemorrhage will occur after 
major surgery or intense traumatism.
The number of the hemorrhagic episodes will be diffe-
rent in each patient. The most frequent is in the locomo-
tor system, in particular the articular bleeding or hemar-
throsis, arising in the early childhood (1,4,6,12).
The moderate or mild A type hemophiliacs can be trea-
ted in most occasions with DDAVP and antifibrinolytic 
agents. In those classified as severe, it is mandatory the 
use of substitutive treatments with FVIII or FIX, as re-
quired, which can be as purified or combinant plasma 
concentrate (1,4,6). The dosage will be the same as for 
the vWD and it is necessary reaction test to DDAVP in 
patients with type A moderate or mild, as it may allow 
avoiding the administration of concentrates.
- Dental considerations in the patient with vWD and he-
mophilia
In patients with moderate or mild hemophilia, the non-
surgical dental practises may proceed under the admi-
nistration of antyfibtinolytic agents (tranexamic acid or 
epsilon-aminocaproic acid) and consulting with a hae-
matologist before making any other procedure. 
In patients with mild hemophilia A (FVIII >10%) and 
the majority of patients with vWD (type I), it is possible 
to dental prophylaxis and some minor surgical interven-
tion under administration of DDAVP.
In patients with severe hemophilia, it is necessary the 
replacement of the factor before the surgery, local anes-
thetic injections or dental prophylaxis. As for example, 
with a patient with type A hemophilia, before a dental 
extraction it is recommended a dose of 50 UI/kg of 
FVIII; and in the case it is type B, the dose will be of 
100 IU/kg of FIX.
Previous to dental extractions it can also be administrated 
epsilon-aminocaproic acid (Caproamin®) or tranexámic 
acid (amchafibrin®), at prophylactic doses of 20mg/kg 
every 9 hours, starting 48 hours before the intervention 
and continuing until the surgical wound closes (7-10 
days after) (4,12).
Economic and safety method to control the hemorrhage, 
is to rinse the mouth before and after the dental extrac-
tion with tranexamic acid. The recommendation is to 
rinse with 10 ml of a 5% solution during two minutes, 
four times a day during 7 days. Additionally, before any 
invasive procedure, including dental manipulation, it is 
necessary the detection of any FVIII inhibitors. 
Patients with antiplatelet drugs
- Antiplatelet agents:
Antiplatelet drugs are frequently used for prevention 
of arterial and venous thrombosis in patients suffering 
ischemic cardiopathy, as well as on carriers of prosthe-
tic heart valves and coronary endoprosthesis (stent) and 
patients with risk of experimenting an ischemic stroke. 
This treatment provides an evident benefit to patients 
that has suffered, recent or non-recent, acute myocardial 
infarction (AMI), cerebral straction, transitory cerebral 
ischemia and patients classified as high risk for throm-
botic episodes (13). The most used drug is Acetylsali-
cylic acid, with clopidogrel and dipiridamol (14) and the 
trifusal.
Acetylsalicylic acid (ASA) (Aspirina®, Adiro®, • 
Biopak®, Tromalyt®):
ASA is the only non-steroidal anti-inflammatory medi-
cament used in the prevention and treatement of throm-
boembolic disease (14,15). The ASA de-activates the 
Cyclooxygenase enzyme, making it irreversible for pla-
telet life cycle (15). This enzyme is responsible for the 
development of prostaglandins and thromboxane A2, in-
volved in the activation mechanisms and platelet aggre-
gation. This defect will persist during platelet lifetime, 
10 days (14). The range of dose is between 20-300 mg/
day.
Several studies conclude, that in order to prevent, in 
the long term, thrombotic events in high-risk patients, 
it is recommended the daily use of AAS. A daily dose 
of AAS of 75-150 mg will help prevention without any 
significant increase of bleeding during and after dental 
extraction (14,15).
 Clopidogrel (Plavix®) y Ticlopidine (Tiklid®):• 
Clopidogrel and Ticlopidine are members of the family 
of the thienopyridines. This antiplatelet drugs act over 
the receptors of the adenosine diphosphate, involved in 
platelets aggregation. They are recommended in resis-
tant thromboembolic diseases or intolerant to ASA, as 
well as if there is a higher risk of cerebral ischemia.
The Ticlopidine (Tiklid®, Ticlodone®), seems to be 
more effective than ASA for the prevention of cerebro-
vascular accidents however it has more side effects, like 
anaemia and neutropenia. The diary dose is of 250 mg/
day.  
Dipyridamole (Persantin®):• 
Dipyridamole action mechanism is the inhibition of pla-
telets aggregation increasing the levels of 3´5´-adenosine 
cyclic monophosphate. In addition it will also have va-
sodilating effects due to the stimulus it exerts over the 
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synthesis of prostacyclin. On its own it has no influence 
on the hemorrhage time nor in the platelets aggregation. 
The side effects are headache, dizziness, muscle weak-
ness and gastrointestinal symptoms. The dosage is 75 
mg/day. 
Triflusal (Disgren):• 
In this case, Triflusal acts inhibiting the synthesis of the 
prostanoids through an irreversible blockage (by ace-
tylation) of cyclooxygenase, impeding de physiologi-
cal synthesis of antiplatelet factors (prostacycline) and 
proagregants (thromboxane A2). The recommendation 
on the dosage is in adults of 300 mg/24h.
- Dental management of patient with antiplatelet drugs:
A few years ago, due to the haemorrhage risk in the post-
surgery, the recommendation was to withdraw antiplate-
let use from 7 to 10 days before the intervention. Now 
a day, even though every dental invasive procedure has 
associated a risk of oral hemorrhage, it is not specified 
to stop the antiplatelet treatment, as the risk of throm-
boembolism associated could be higher than the risk of 
haemorrhage.
Therefore, there will not be suppression of the antiplate-
let treatment, and the approach will include local measu-
res to ensure a good haemostasis through pressure with 
a gauze, oxidized celullose, stitches, gauze soaked with 
tranexamic acid (Amchafibrin®) (13,15). 
Coronary Stents:• 
The stent is a mechanical device that holds the artery 
open, with a structure obtaining a more circular cir-
cumference, and smooths the internal contour of the ar-
tery. The material has to be biocompatible and resistant 
to thrombosis, to migracion and to the extrinsic com-
pression (radial force).
Stents are classified into two different groups, metallic 
and pharmaco-active (the drug is incorporated in a poly-
meric mold attached to the metallic surface of the stent, 
and will release the medicine in controlled basis to the 
arterial wall).
Dental considerations of the patient with coronary 
stents:
Patients that carry stents, metallic or pharmaco-active 
stents will both receive a treatment with aspirin, usually 
combined with clopidogrel (has been proved to be more 
effective in combination, to reduce the risk of cardiac 
episodes). The guidelines for patients carriers of stent 
are the following (16):
Minor surgery, dental prophylaxis or dental extrac-• 
tions can be performed with a small risk of hemorr-
hage, without the need of withdrawing the antiplate-
let treatment (using local measures to ensure a good 
hemostasis) (13).
Non-urgent invasive procedures with significant risk • 
of hemorrhage will be delayed at least one month 
for patients with metallic stents and to 12 months 
to patients with pharmaco-active stents, instead of 
withdrawing the antiplatelet activity.
In patients that it is necessary a surgical intervention • 
that requires the withdraw of antiplatelet treatment 
with clopidogrel, the aspirin will not be withdrawn 
and clopidogrel will be re-established as soon as 
possible to prevent thrombosis of the stent.
Anticoagulated patients:
- Oral anticoagulants (OAC):
OAC are used in treatments for venous thromboembo-
lism and in the prevention of heart attack and systematic 
embolism in patients with auricular fibrillation, cardiac 
valvular disease or with metallic valve prostheses (3,17-
19). Now a days, warfarin sodium (Coumadin®) (14,17-
19), is the most popular in Anglo-Saxon countries and 
acenocumarol (Sintrom®) is the most used in Spain, 
which is a derivative of the 4-hydroxycoumarin. Is an 
antagonist of the K vitamin, and inhibits the carboxyla-
tion of glutamate in the amino terms of these proteins. 
The warfarin has two functions: anticoagulant activity 
and antithrombotic effect. The ACO is monitored by its 
effect on the Prothrombin time (PT). Generally, the PT 
results will be expressed as time of patient / time of con-
trol. In 1983 the WHO introduced the INR (International 
Normalized Ratio). The therapeutic levels of anticoagu-
lation that should be preserved on patients depending on 
the kind of pathology will oscillate the INR between 2 to 
3 (14,17-19), except for cardiac valvular prosthesis that 
should have INR maintained between 2,5 and 3,5 (1). 
Existing a strong correlation between INR and risk of 
hemorrhage, increasing when the INR > 3.
- Dental management of  the anticoagulated patient:
The procedure with a patient with coagulation disturban-
ces that is going to be subject to a dental extraction is 
described in the following recommended guideline:
The INR must be checked the same day of the 1. 
surgery. A simple exodontia will take place if the 
results are within the therapeutic values (2-3 or 2,5-
3,5, depending on the pathology) (Normal values of 
INR is 1.0). If the results are within these therapeutic 
values, there will not be any modification in the 
anticoagulant treatment (14,17-19). Applying local 
measures can control the possible hemorrhage, and 
withdrawing the treatment will not necessarily reduce 
the hemorrhage and could lead to thromboembolic 
complications. 
In the case of a surgical exodontia, it will be requi-
red to consult a haematologist, in order to decide on 
the withdrawal of the ACO 2-3 days before the in-
tervention, substituting it by low molecular weight 
heparin (LMWH). Be administered prophylactic 
doses of LMWH if the INR daily checked is < 2.0, 
overlapping two anticoagulants from the day after 
surgery, to achieve the desired values (3). 
The dental extraction will be done as carefully as 2. 
possible, minimising traumatism of soft tissue, 
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avoiding any major hemorrhage.
Once the exodontia is completed, proceed with lo-3. 
cal hemostatic measures with re-absorbable fibrin 
adhesives (Tissucol®), oxidized cellulose or gelatin 
sponges to help clot formation (8,17-20).
Proceed with silk or re-absorbable stitches (in or-4. 
der to reduce the risk of hemorrhage when take off), 
joining both sides, and impede the release of the he-
mostatic agent from the alveolus. 
Compression with a gauze soaked in tranexamic acid 5. 
(Amchafirin®) (8,14,17,18), during 20-30 min.
Revision of the surgical wound after 20 min.6. 
Prevention is the most important measure of them all (8). 
In table 1, a number of recommendations can be found 
to follow in patients with hemostasis disturbances.
The main complication that may arise, in patients with 
hemostasis alterations as well as in anticoagulated and 
antiagregated patients, is a post-surgical hemorrhage. 
The recommended guidelines are described in table 2.
Conclusively, a number of protocols and guidelines have 
been defined for the procedures with anticoagulated and 
antiagregated patients, from the odontological point of 
view. 
In patients with antiplatelet drugs  that are subject of a 
simple therapy there will not be modifications in the an-
tiplatelet treatment, instead local measures will be prac-
tised in order to ensure a good hemostasis. In combined 
therapies it will be possible to proceed in the same way 
involving minor surgery, dental prophylaxis or dental 
extraction without modifying the antiplatelet treatment. 
(local haemostatic measures)
Moreover, in patients that it is necessary a surgical in-
tervention that requires the withdraw of antiplatelet 
treatment with clopidogrel, the aspirin will not be wi-
thdrawn and clopidogrel will be re-established as soon 
as possible.
Prevention of the complications
Identification of the patient by a detailed medical history: disease antecedents, exploration and laboratory tests 1. 
for selective indentification (1,2,8).
Enhance the oral hygiene to avoid invasive dental treatments2. 
Consultation with the hematologyst, to know the kind of congenital disorder, or to learn the extent of the pacient 3. 
anticoagulation.
Do not perform surgery if platelets count is less tan 50,000 platelets.4. 
 Replacement therapy of coagulation factor déficit if necessary.5. 
(hemophilia A and B and vWD)(1,10-12).6. 
Value the hospital admission for complex surgery in the case of hemophilia.7. 
Do not use ASA or its derivatives for treatment of pain. Paracetamol is a safe alternative.8. 
Coumarin interactions with another drugs: antibiotics (amoxicillin and amoxicillin plus clavulanate, ampicillin, 9. 
azithromycin, erythromycin, rifampicin, penicillin G, cephalosporins, sulfonamides, metronidazole, chloram-
phenicol), antifungals (azoles and griseofulvin), analgesics (aspirin and other nonsteroidal antiinflammatory 
drugs; paracetamol in excess can enhance warfarin action), and psychoactive drugs (some antihistamines, dia-
zepam) (1).
Consultations in the morning, in order to resolve any complication during the day.10. 
Avoid, if posible, nerve block anesthesia.11. 
Preferable endodontics or restorative treatment to dental extractions.12. 
Table 1. Recomendations to avoid complications.
Treatment of the complications
Remove stitches.1. 
Clean the clot to identify the bledding site.2. 
Local anesthesia with epinephrine (lidocaine 2% with epinephrine 1:80.000 to 1:200.000).3. 
Tamponade of alveolus, stitches.4. 
Compression with gauze soaked with tranexamic acid (Amchafibrin®).5. 
Acetate desmopressin if persistent bleeding.6. 
Rinses with antifibrinolytics 4 times a day, 7 days (19).7. 
Table 2. Treatment of the complications in patients with hemostasis alterations.
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In anticouagulated patients, the INR will be measured 
the same day of the intervention. If INR is higher than 
normal values or it is a surgical intervention, a haemato-
logist should be consulted in order to decide on the with-
draw of the ACO treatment, substituting it with LMWH. 
Complemented with local hemostatic measures.
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